Lenalidomid Stada

Lenalidomide, the active ingredient in Lenalidomid Stada, is an immunomodulatory agent presented as an oral tablet for use in adult patients. It is employed in the management of multiple myeloma and myelodysplastic syndromes with deletion 5q, providing anti‑angiogenic and immune‑modulating effects.

GNH USA supplies Lenalidomid Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product conforms to EU regulatory requirements and is distributed under controlled conditions to ensure product integrity through a network of certified logistics partners.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders.

- Multiple myeloma: used in combination regimens to improve disease control, delay progression, and extend overall survival in eligible patients. - Myelodysplastic syndromes with del(5q): administered to reduce red‑cell transfusion requirements and to increase hemoglobin levels, offering a disease‑modifying effect. - Relapsed or refractory multiple myeloma: provides an additional line of therapy for patients whose disease has progressed after prior treatments.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Neutropenia - Thrombocytopenia - Anemia - Fatigue - Diarrhea

Serious or Rare Side Effects: - Venous thromboembolism - Severe skin reactions such as Stevens‑Johnson syndrome - Secondary primary malignancies

Before initiating lenalidomide, several precautionary measures should be observed to ensure patient safety.

- Blood count monitoring: Regular complete blood count monitoring is required to detect cytopenias early. - Thromboembolic risk assessment: Assess for risk factors of thrombosis and consider prophylactic anticoagulation when appropriate. - Pregnancy prevention: Lenalidomide is teratogenic; effective contraception must be used by both male and female patients of reproductive potential. - Renal function adjustment: Dose adjustment may be needed in patients with impaired renal function. - Drug interaction review: Review concomitant medications for potential interactions, especially strong CYP3A4 inducers. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Concurrent use with other immunomodulatory agents: increases risk of severe cytopenias.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): may increase bleeding risk; monitor coagulation parameters. - P‑glycoprotein inhibitors (e.g., cyclosporine): may increase plasma levels; observe for toxicity. - CYP3A4 inhibitors (e.g., ketoconazole): may modestly increase exposure; consider dose adjustment.